Esperion Therapeutis.Inc. buy dartajon99
Start price
22.05.23
/
50%
€1.53
Target price
22.06.23
-
Performance (%)
-17.49%
End price
23.06.23
€1.26
Summary
This prediction ended on 23.06.23 with a price of €1.26. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -17.49%. dartajon99 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -6.740% | -6.740% | 107.275% |
| iShares Core DAX® | 3.593% | 3.931% | 15.378% |
| iShares Nasdaq 100 | 5.810% | 5.518% | 41.455% |
| iShares Nikkei 225® | 4.075% | 8.460% | 48.947% |
| iShares S&P 500 | 4.142% | 4.039% | 31.594% |
According to dartajon99 what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by dartajon99 for this prediction
In the thread Trading Esperion Therapeutis.Inc.
Die von dartajon99 gewählte maximale Laufzeit wurde überschritten
